These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22531916)

  • 1. Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells.
    Ding W; Manni M; Stohl LL; Zhou XK; Wagner JA; Granstein RD
    Eur J Immunol; 2012 Apr; 42(4):901-11. PubMed ID: 22531916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
    Delgado M; Leceta J; Gomariz RP; Ganea D
    J Immunol; 1999 Oct; 163(7):3629-35. PubMed ID: 10490956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal peptide modulates Langerhans cell immune function.
    Kodali S; Ding W; Huang J; Seiffert K; Wagner JA; Granstein RD
    J Immunol; 2004 Nov; 173(10):6082-8. PubMed ID: 15528344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research on the mechanism of prednisone in the treatment of ITP via VIP/PACAP-mediated intestinal immune dysfunction.
    Yan X; Zhang Y; Lang H; Huang Z; Chen X; He H; Zhao Q; Wang J
    Eur J Med Res; 2023 Feb; 28(1):67. PubMed ID: 36750876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
    Delgado M; Reduta A; Sharma V; Ganea D
    J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M; Ganea D
    J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
    Ganea D; Delgado M
    Crit Rev Oral Biol Med; 2002; 13(3):229-37. PubMed ID: 12090463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonin Gene-Related Peptide-Exposed Endothelial Cells Bias Antigen Presentation to CD4+ T Cells toward a Th17 Response.
    Ding W; Stohl LL; Xu L; Zhou XK; Manni M; Wagner JA; Granstein RD
    J Immunol; 2016 Mar; 196(5):2181-94. PubMed ID: 26829986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M; Jonakait GM; Ganea D
    Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
    Delgado M; Ganea D
    J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
    Ganea D; Delgado M
    Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide.
    Delgado M; Leceta J; Abad C; Martinez C; Ganea D; Gomariz RP
    J Neuroimmunol; 1999 Sep; 99(1):61-71. PubMed ID: 10496178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of T helper cell responses during antigen presentation by norepinephrine-exposed endothelial cells.
    Xu L; Ding W; Stohl LL; Zhou XK; Azizi S; Chuang E; Lam J; Wagner JA; Granstein RD
    Immunology; 2018 May; 154(1):104-121. PubMed ID: 29164596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary adenylate cyclase-activating polypeptide promotes cutaneous dendritic cell functions in contact hypersensitivity.
    Yamamoto Y; Otsuka A; Ishida Y; Wong LS; Seidel JA; Nonomura Y; Nakashima C; Nakajima S; Kitoh A; Nomura T; Dainichi T; Honda T; Amano W; Konishi N; Hayashi M; Matsushita M; Kabashima K
    J Allergy Clin Immunol; 2021 Sep; 148(3):858-866. PubMed ID: 33609627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes.
    Martinez C; Delgado M; Gomariz RP; Ganea D
    J Immunol; 1996 Jun; 156(11):4128-36. PubMed ID: 8666779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.